This is very interesting.
https://news.ohsu.edu/2025/08/14/ohsu-knight-...nny-knight
OHSU Knight Cancer Institute Director Brian Druker, M.D. and his connection to
Jonah B. Sacha, PhD
Dr. Sacha graduated cum laude from the University of Missouri-Columbia in 2003 with a B.A. in German and B.S. in Biology. After receiving his Ph.D. in Medical Microbiology & Immunology from the University of Wisconsin-Madison in 2007, he joined the faculty at UW-Madison, where he researched the characteristics of effective retrovirus-specific CD8+ and CD4+ T cells. In 2011, he joined the Oregon Health & Science University and has appointments in both the Vaccine & Gene Therapy Institute and Oregon National Primate Research Center.
What's the relationship between the Knight Cancer Institute and the new Knight Cancer Group?
The relationship between the OHSU Knight Cancer Institute and the new Knight Cancer Group is a matter of organizational restructuring within OHSU.
The OHSU Knight Cancer Institute is a research institute within OHSU focused on cancer research and treatment. It is an NCI-designated Comprehensive Cancer Center.
The Knight Cancer Group is a newly established entity with its own board of directors. Its purpose is to govern the OHSU Knight Cancer Institute and manage OHSU's cancer services.
The creation of the Knight Cancer Group makes the Knight Cancer Institute a self-governed entity within OHSU, providing it with more independence in its operations.
Brian Druker, previously the Director and CEO of the Knight Cancer Institute, has returned to a leadership role as the inaugural president of the Knight Cancer Group. This allows him to align the responsibility of utilizing the recent record-setting $2 billion donation with the authority to do so effectively.
In essence, the Knight Cancer Group acts as an overarching governance structure for the OHSU Knight Cancer Institute and all of OHSU's cancer services, allowing for a more integrated and streamlined approach to cancer care and research, particularly with the recent influx of funding from Phil and Penny Knight.
How's the $2B donation allocated?
The $2 billion donation from Phil and Penny Knight to the OHSU Knight Cancer Institute is allocated to achieve several key objectives aimed at transforming cancer research and patient care.
The allocation focuses on:
Expanding and accelerating diagnostics: The funding will allow for advancements in how cancer is detected and diagnosed, leading to earlier and potentially more effective interventions.
Ensuring access to innovative clinical trials: The donation will support the expansion of clinical trials, providing patients with access to cutting-edge treatments and research discoveries by Knight Cancer Institute researchers.
Bolstering patient support services: The gift emphasizes a holistic approach to patient care, funding a range of resources like:
Nutritional support
Psychological, genetic, and financial counseling
Symptom management
Survivorship care and support
Other complementary therapies
Simplifying the patient experience: The aim is to create a more streamlined and less daunting experience for patients and their families navigating the cancer journey.
This substantial donation, to be disbursed over 10 years, will also allow the Knight Cancer Institute to become a self-governed institution within OHSU. This new structure, with its own board of governors and the ability to set compensation rates, will enable the Institute to attract top research talent and enhance its competitive edge in the national landscape of cancer research. OHSU News reports that this investment was inspired by Dr. Druker's vision to integrate scientific discovery with unmatched patient care.
https://news.ohsu.edu/2025/08/14/ohsu-knight-...nny-knight
OHSU Knight Cancer Institute Director Brian Druker, M.D. and his connection to
Jonah B. Sacha, PhD
Dr. Sacha graduated cum laude from the University of Missouri-Columbia in 2003 with a B.A. in German and B.S. in Biology. After receiving his Ph.D. in Medical Microbiology & Immunology from the University of Wisconsin-Madison in 2007, he joined the faculty at UW-Madison, where he researched the characteristics of effective retrovirus-specific CD8+ and CD4+ T cells. In 2011, he joined the Oregon Health & Science University and has appointments in both the Vaccine & Gene Therapy Institute and Oregon National Primate Research Center.
What's the relationship between the Knight Cancer Institute and the new Knight Cancer Group?
The relationship between the OHSU Knight Cancer Institute and the new Knight Cancer Group is a matter of organizational restructuring within OHSU.
The OHSU Knight Cancer Institute is a research institute within OHSU focused on cancer research and treatment. It is an NCI-designated Comprehensive Cancer Center.
The Knight Cancer Group is a newly established entity with its own board of directors. Its purpose is to govern the OHSU Knight Cancer Institute and manage OHSU's cancer services.
The creation of the Knight Cancer Group makes the Knight Cancer Institute a self-governed entity within OHSU, providing it with more independence in its operations.
Brian Druker, previously the Director and CEO of the Knight Cancer Institute, has returned to a leadership role as the inaugural president of the Knight Cancer Group. This allows him to align the responsibility of utilizing the recent record-setting $2 billion donation with the authority to do so effectively.
In essence, the Knight Cancer Group acts as an overarching governance structure for the OHSU Knight Cancer Institute and all of OHSU's cancer services, allowing for a more integrated and streamlined approach to cancer care and research, particularly with the recent influx of funding from Phil and Penny Knight.
How's the $2B donation allocated?
The $2 billion donation from Phil and Penny Knight to the OHSU Knight Cancer Institute is allocated to achieve several key objectives aimed at transforming cancer research and patient care.
The allocation focuses on:
Expanding and accelerating diagnostics: The funding will allow for advancements in how cancer is detected and diagnosed, leading to earlier and potentially more effective interventions.
Ensuring access to innovative clinical trials: The donation will support the expansion of clinical trials, providing patients with access to cutting-edge treatments and research discoveries by Knight Cancer Institute researchers.
Bolstering patient support services: The gift emphasizes a holistic approach to patient care, funding a range of resources like:
Nutritional support
Psychological, genetic, and financial counseling
Symptom management
Survivorship care and support
Other complementary therapies
Simplifying the patient experience: The aim is to create a more streamlined and less daunting experience for patients and their families navigating the cancer journey.
This substantial donation, to be disbursed over 10 years, will also allow the Knight Cancer Institute to become a self-governed institution within OHSU. This new structure, with its own board of governors and the ability to set compensation rates, will enable the Institute to attract top research talent and enhance its competitive edge in the national landscape of cancer research. OHSU News reports that this investment was inspired by Dr. Druker's vision to integrate scientific discovery with unmatched patient care.
13
1
